Key issues in stratified treatment of HER2 positive breast cancer at different stages

doi:10.3877/cma.j.issn.1674-0785.2020.11.002

Abstract

Abstract:

In recent years, the clinical research of anti-HER2 drugs has made many breakthroughs, which has significantly improved the prognosis of HER2 positive breast cancer patients and changed the diagnosis and treatment mode of breast cancer. The 2020 edition of the Chinese Society of Clinical Oncology (CSCO) breast cancer diagnosis and treatment guidelines has made important updates to the pre-operative neoadjuvant treatment, postoperative adjuvant treatment, and recurrence and metastasis management of HER2 positive breast cancer, given treatment recommendations for patients with different stages of breast cancer, and standardized the clinical diagnosis and treatment of this malignancy, aiming to improve the survival rate and the quality of life of patients.

Key words: Breast cancer, Human epidermal growth factor receptor-2, CSCO guideline update

Xueli Mo, Jie Dong, Dong Han. Key issues in stratified treatment of HER2 positive breast cancer at different stages[J]. Chinese Journal of Clinicians(Electronic Edition), 2020, 14(11): 862-865.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcyszz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0785.2020.11.002

https://zhlcyszz.cma-cmc.com.cn/EN/Y2020/V14/I11/862

References 23

1	Broglio KR, Quintana M, Foster M, et al. Association of pathologic complete response to neoadjuvant therapy in HER2-positive breast cancer with long-term outcomes: A Meta-Analysis [J]. JAMA Oncol, 2016, 2(6): 751-760.
2	Von MG, Huang CS, Mano MS, et al. Trastuzumab Emtansine for residual invasive HER2-positive breast cancer [J]. N Engl J Med, 2019, 380(7): 617-628.
3	Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer [J]. J Clin Oncol, 2005, 23(16): 3676-3685.
4	Izumi Y, Xu L, Di TE, et al. Tumour biology: herceptin acts as an anti-angiogenic cocktail [J]. Nature, 2002, 416(6878): 279-280.
5	Gianni L, Pienkowski T, Im YH, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial [J]. Lancet Oncol, 2016, 17(6): 791-800.
6	Shao Z, Pang D, Yang H, et al. Efficacy, safety, and tolerability of Pertuzumab, Trastuzumab, and Docetaxel for patients with early or locally advanced ERBB2-positive breast cancer in Asia: The PEONY phase 3 randomized clinical trial [J]. JAMA Oncol, 2019, 6(3): e193692.
7	Hurvitz SA, Martin M, Symmans WF, et al. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial [J]. Lancet Oncol, 2018, 19(1): 115-126.
8	Hurvitz SA, Martin M, Jung KH, et al. Neoadjuvant Trastuzumab Emtansine and Pertuzumab in human epidermal growth factor receptor 2-positive breast cancer: Three-year outcomes from the phase III KRISTINE study [J]. J Clin Oncol, 2019, 37(25): 2206-2216.
9	Geyer JCE, Huang CS, Mano MS, et al. Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: Primary results from KATHERINE [J]. Cancer Research, 2019, 79(4): GS1-10.
10	Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial [J]. Lancet, 2017, 389(10075): 1195-1205.
11	Perez EA, Romond EH, Suman VJ, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31 [J]. J Clin Oncol, 2011, 29(25): 3366-3373.
12	Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer [J]. N Engl J Med, 2011, 365(14): 1273-1283.
13	Tolaney SM, Guo H, Pernas S, et al. Seven-year follow-up analysis of adjuvant Paclitaxel and Trastuzumab trial for node-negative, human epidermal growth factor receptor 2-positive breast cancer [J]. J Clin Oncol, 2019, 37(22): 1868-1875.
14	Piccart M, Procter M, Fumagalli D, et al. Interim overall survival analysis of APHINITY (BIG 4-11): A randomized multicenter, double-blind, placebo-controlled trial comparing chemotherapy plus trastuzumab plus pertuzumab versus chemotherapy plus trastuzumab plus placebo as adjuvant therapy in patients with operable HER2-positive early breast cancer [J]. Cancer Res, 2020, 80(4): GS1-04.
15	Martin M, Holmes FA, Ejlertsen B, et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial [J]. Lancet Oncol, 2017, 18(12): 1688-1700.
16	Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 [J]. N Engl J Med, 2001, 344(11): 783-792.
17	Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group [J]. J Clin Oncol, 2005, 23(19): 4265-4274.
18	Wardley AM, Pivot X, Morales-Vasquez F, et al. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer [J]. J Clin Oncol, 2010, 28(6): 976-983.
19	Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer [J]. N Engl J Med, 2015, 372(8): 724-734.
20	Zhou X, Cella D, Cameron D, et al. Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment [J]. Breast Cancer Res Treat, 2009, 117(3): 577-589.
21	Yan M, Bian L, Hu XC, et al. Pyrotinib plus capecitabine for human epidermal factor receptor 2-positive metastatic breast cancer after trastuzumab and taxanes (PHENIX): a randomized, double-blind, placebo-controlled phase 3 study [J]. Transl Breast Cabcer Res, 2020, 1(13): 18-30.
22	Diéras V, Miles D, Verma S, et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial [J]. Lancet Oncol, 2018, 19(12): E667-E667.
23	Modi S, Saura C, Yamashita T, et al. Trastuzumab Deruxtecan in previously treated HER2-positive breast cancer [J]. N Engl J Med, 2020, 382(7): 610-621.

[1]	Xu Zhang, Jianping Xu, Dongming Su, Caifen Wang, Dali Wang, Wenzhi Zhang. Contrast-enhanced ultrasound features of male breast masses [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(08): 854-859.
[2]	Hua Shao, Ziyue Na, Hui Jing, Bo Li, Qiucheng Wang, Wen Cheng. Value of preoperative percutaneous contrast-enhanced ultrasound in diagnosis of axillary sentinel lymph node metastasis and burden in breast cancer [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(08): 849-853.
[3]	Meiwu Zhang, Shuyi Lyu, Xiaoxiang Fan, Luhui Zhuang, Yuqin Qiu, Baisong Zhang, Yan Zhang. Clinical value of ultrasound-guided aspiration combined with hypertonic glucose flushing in treatment of postoperative subcutaneous effusion in patients with breast cancer [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(03): 327-331.
[4]	Xiaowei Qi, Songqing Ye. Landscape of antibody-drug conjugates for breast cancer treatment [J]. Chinese Journal of Breast Disease(Electronic Edition), 2023, 17(03): 129-135.
[5]	bing Feng, Qiuguo Zou, Zhenbo Liang, Yanming Lu, Yi Zeng, Shumiao Wu. Clinical study of ultrasonic signs and molecular biological indicators of senile non-specific invasive breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 48-51.
[6]	Yansong Li, Huimin Feng, Mingchao Liu, Zepeng Liu, Qiuxia Jiang. Expression and clinical significance of STIP1 in triple negative breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 52-56.
[7]	Changqing Cao, Xinyan Guo, Yuan Gao, Cun Zhang, Haili Tang, Dong Fan, Xiaojun Yang, Song Zhang, Huadong Zhao. Research progress on the involvement of tumor microenvironment in mediating trastuzumab resistance in HER2-positive breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 90-95.
[8]	Jia Wang, Baoliang Guo, Shan Wang, Dianlong Zhang, Mijia Wang, Tianyang Zhou, Jianguo Zhang, Feng Jin. Interpretation of clinical practice guidelines for diagnosis and treatment of de novo stage Ⅳ breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(03): 250-254.
[9]	Yating Wu, Shenghang Zhang, Shuiliang Wang. Research progress in the role of dysregulated RNA m⁶A modification in breast cancer metastasis [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2023, 13(01): 45-52.
[10]	Ruixue Yue, Lingxin Kong, Xin Hao, Jinqiang Yang, Meng Han, Guozhong Cui, Jianjun Wang, Zhisheng Zhang, Fanting Kong, Wei Zhang, Wenbo He, Xianqiao Li, Xinping Zhou, Donghong Xu, Chongzhu Hu. HER2 protein expression levels predict efficacy of neoadjuvant therapy in breast cancer: A real-world study [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(07): 765-770.
[11]	Fei Liu, Yingxin Wang, Xing Ma, Ling Xin, Yuanjia Cheng, Qian Liu, Yue Wang, Junjun Zhang. Different conductive media for intracavitary electrocardiogram-guided arm port implantation among breast cancer patients: a randomized controlled trial [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(07): 760-764.
[12]	Jiayi Li, Hong Zhang, Jingming Ye, Yinhua Liu, Ling Xu, Shuang Zhang. Androgen receptor: discoveries in breast cancer clinical practice [J]. Chinese Journal of Clinicians(Electronic Edition), 2022, 16(11): 1031-1038.
[13]	Yilin Xu, Hong Lu, Xuejing Liu, Yujuan Hao, Ziling Yu, Ying Zhu. Value of imaging progress in precise axillary treatment of breast cancer [J]. Chinese Journal of Clinicians(Electronic Edition), 2022, 16(11): 1054-1061.
[14]	Qing Chen, Kejin Wu. Interpretation of basic contents of Clinical Practice China Guidelines for Breast Cancer during Pregnancy and Lactation (2022 edition) [J]. Chinese Journal of Clinicians(Electronic Edition), 2022, 16(11): 1050-1053.
[15]	Zeyu Cai, Huimin Lan, Ting Yu, Hui Luo. The study based on Ti₃C₂ loaded with doxorubicin and combined with photothermal therapy for inhibiting the proliferation of breast cancer cells [J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2023, 11(02): 140-145.

Please choose a citation manager

Content to export